Template-activator bifunctional unit-based cross-lesion synthesis driving Cas12a activity grading regulation method and application thereof
Through the template-activator dual-function unit (TAC) combined with the trans-lesion synthesis characteristics of T7 RNA polymerase, the DNA damage site was designed to regulate the length of crRNA, solving the complexity and non-specific activation of the CRISPR/Cas12a system, and achieving fine regulation and high-sensitive detection of Cas12a activity.
Patent Information
- Application Number
- CN202510529748.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-04-25
- Publication Date
- 2025-08-01
AI Technical Summary
The existing CRISPR/Cas12a system has complex activity regulation methods, and relying on exogenous activators to cause non-specific activation risks, making it difficult to achieve fine and hierarchical activity regulation, and it is complex in operation and high in cost, making it difficult to meet the needs of different detection scenarios.
Using the template-activator dual-function unit (TAC), combined with the trans-lesion synthesis characteristics of T7 RNA polymerase, the length of crRNA is accurately regulated to achieve graded regulation of Cas12a activity by designing DNA damage sites at the template and activator levels, and avoiding exogenous activators and complex crRNA modifications.
It realizes fine-level grading regulation of Cas12a activity, simplifies operational steps, reduces costs, reduces the risk of non-specific activation, improves detection sensitivity and applicability, and is suitable for early cancer diagnosis and high-sensitivity detection of biosensors.
Smart Images

Figure CN120400304A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the fields of bioanalysis detection and biosensing, and particularly relates to a method for hierarchical regulation of Cas12a activity driven by translesion synthesis based on template-activator bifunctional units and its applications. Background Art
[0002] Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR) and its associated proteins (CRISPR associated protein, Cas) are part of the prokaryotic adaptive immune system and can effectively resist the invasion of foreign genetic materials such as phages or plasmids. In the field of biosensing, the Cas12a protein has become one of the most concerned and widely used Cas proteins due to its unique nuclease activity and application advantages. The CRISPR array is transcribed as a template to generate CRISPR RNA (crRNA). Among them, the crRNA contains a fixed scaffold motif and a variable spacer sequence complementary to the target nucleic acid. Under the guidance of the crRNA, Cas12a specifically recognizes and targets the cleavage of double-stranded DNA (dsDNA) containing the protospacer adjacent motif (PAM) sequence or single-stranded DNA (ssDNA) without PAM, that is, cis-cleavage activity. At the same time, Cas12a also has a unique and highly efficient non-specific single-stranded DNA trans-cleavage activity, that is, it can repeatedly cycle to cleave any ssDNA molecule nearby after recognizing the target DNA. This trans-cleavage activity endows Cas12a with a novel signal amplification mechanism and provides important support for rapid and highly sensitive nucleic acid detection.
[0003] Currently, the methods for regulating the activity of the CRISPR / Cas12a system have shown great potential in the fields of molecular diagnosis and biosensing. In addition to the direct modification of the Cas12a protein, it mainly relies on the changes in activators, such as the design of pivot-mediated PAM-motif-independent activators, split activators, etc. However, most of these methods rely on exogenously provided activators, resulting in an increase in the complexity of the reaction system and a risk of non-specific activation of Cas12a in the absence of target DNA, thereby generating off-target effects and limiting its compatibility with the upstream reaction network to a certain extent, thus restricting the programmability and flexibility of the CRISPR / Cas system. On the other hand, the modification of crRNA has gradually become a research hotspot, such as elongating cage-like crRNA, circular crRNA, extending DNA / RNA / G-quadruplex (G4) at the end of crRNA, chemically modifying crRNA (N6-methyladenosine, 2'-O-methyl), etc., to achieve signal transduction switching and the regulation of Cas12a activity. However, these strategies usually involve complex crRNA modification processes and may require repeated optimization of the design, increasing the experimental difficulty and cost. In addition, the above methods are mostly single "one-touch" activation methods, which can only achieve rough regulation and are difficult to meet the requirements for fine and hierarchical regulation of Cas12a activity in different detection scenarios. In view of the above problems, it is particularly important to develop new regulatory mechanisms, especially while maintaining high activity, simplifying the operation steps, reducing the economic cost, and being able to finely regulate the activity of Cas12a.
[0004] T7 RNA polymerase (T7 RNAP) is often used as a powerful tool for preparing crRNA due to its strong transcriptional activity. At the same time, T7 RNAP also has the ability of translesion synthesis and plays an important DNA damage sensing function in the process of transcription-coupled repair. There are various types of DNA lesions, among which deoxyuridine bases (dU) and apurinic / apyrimidinic (AP) sites are the most common. These effects may cause T7 RNAP to correctly bypass the lesion, induce transcriptional mutations, or lead to transcriptional stalling. Studies have shown that the incorporation of dU can establish base pairs with a geometric shape closer to Watson-Crick pairing, so T7 RNAP can effectively bypass dU. However, when an AP site is present, the DNA double helix structure is significantly distorted, hindering T7 RNAP from loading onto the correct active site and thus blocking the transcription process. However, the existing methods of combining T7 RNAP with the regulation of Cas12a activity mainly focus on directly activating Cas12a with the crRNA produced by T7 RNAP, ignoring the potential ability of T7 RNAP to finely regulate the specific behavior of lesion sites. Therefore, these methods face problems such as insufficient regulation accuracy, complex operation, and difficulty in expanding to more application scenarios.
[0005] In view of the above challenges, it is particularly urgent to develop a new strategy for efficient and precise regulation of Cas12a activity, especially to fully utilize the ability of T7RNAP to synthesize across lesions, so as to achieve simple, efficient and cost-effective precise regulation. Summary of the Invention
[0006] Aiming at the problems of complexity of system components, high cost of chemical modification, insufficient regulation accuracy and poor flexibility in the existing problems, the object of the present invention is to provide a method for hierarchical regulation of Cas12a activity driven by translesion synthesis based on template-activator bifunctional units and its application. On the basis of the existing methods, for the first time, the functions of the template and the activator are combined simultaneously to develop a TAC unit, so as to achieve the goal of finely regulating the activity of Cas12a without the need to additionally add an activator.
[0007] The technical solution adopted by the present invention to solve its technical problems is as follows:
[0008] In the first aspect, the present invention protects a template-activator bifunctional unit (TAC), and the bifunctional unit comprises:
[0009] (i) T7 promoter and its complementary sequence;
[0010] (ii) CRISPR array sequence for transcribing crRNA;
[0011] (iii) At least one DNA damage site selected from deoxyuridine base (dU) or apurinic / apyrimidinic (AP) site.
[0012] In a specific embodiment, the CRISPR array sequence serves as both a crRNA transcription template and an activator of Cas12a, and the DNA damage site is located at a specific position on the template strand, including at least one position among the 2nd, 12th, 20th, 27th, 33rd or 39th nucleotides.
[0013] In the second aspect, the present invention protects a method for hierarchical regulation of Cas12a activity based on the foregoing TAC unit, comprising the following steps:
[0014] (1) Utilize the efficient transcription property of T7 RNA polymerase to transcribe crRNA through the TAC unit;
[0015] (2) Utilize the translesion synthesis property of T7 RNA polymerase to regulate the length of crRNA by the type and position of the DNA damage site, so as to achieve hierarchical regulation of the trans-cleavage activity of Cas12a.
[0016] The present invention ingeniously combines the lesion - bypass synthesis property of T7 RNAP with the specific nucleic acid cleavage activity of Cas12a. By designing TAC units containing different types of DNA lesion sites (such as dU bases and AP sites), and utilizing the different response behaviors of T7 RNAP to lesion sites during transcription, crRNAs with different lengths are precisely generated. Specifically:
[0017] (a) When the TAC unit contains a dU base, at the template level, T7 RNA polymerase completes the transcription of the full - length crRNA; at the activator level, the modification of the dU base at any position in the CRISPR array does not affect the trans - cleavage activity of Cas12a, thus fully activating the trans - cleavage activity of Cas12a.
[0018] (b) When the TAC unit contains an AP site, at the template level, the transcription of T7 RNA polymerase is blocked, generating truncated crRNAs; at the activator level, apurinic / apyrimidinic sites at different positions can have no effect, inhibit, or partially inhibit the trans - cleavage activity of Cas12a.
[0019] After different - length crRNAs bind to their corresponding activators and Cas12a, significant differences in Cas12a activity will occur, showing a finely controllable hierarchical regulation effect. Through this ingenious design, the template strand not only serves as the crRNA transcription template but also as an activator, which not only avoids the need for exogenous activators and the complex crRNA modification process, effectively simplifies the experimental system and operation steps, but also realizes the hierarchical regulation of Cas12a activity at the template level and the template - activator level.
[0020] In a third aspect, the present invention protects a detection platform based on the aforementioned TAC unit or the aforementioned method. By combining with an aggregation - induced emission (AIE) fluorescent probe, a "Light up" AIE fluorescent signal output platform is constructed for detecting the base excision repair enzyme (UDG), which specifically includes the following steps:
[0021] (1) Using UDG to convert the dU base in the TAC - dU2 unit into an AP site.
[0022] (2) Transcribing through T7 RNA polymerase to generate full - length crRNAs or truncated crRNA fragments to regulate the activity of Cas12a; (3) Triggering the cleavage of the AIE fluorescent probe by the trans - cleavage activity of Cas12a, and quantitatively analyzing the UDG concentration through the change in AIE fluorescent signal.
[0023] In a specific embodiment, the AIE fluorescent probe is a G-quadruplex / hemin system with peroxidase-like activity, which catalyzes the generation of reactive oxygen species from hydrogen peroxide to oxidize Amplex Red to resorufin with typical AIE characteristics.
[0024] In a specific embodiment, the detection limit of the detection platform is 0.0000108 U·mL-1, and the linear range is 0.00005 - 0.0040 U·mL-1.
[0025] Fourthly, the present invention protects the application of the aforementioned TAC unit in the preparation of products for early cancer diagnosis, realizing highly sensitive detection of cancer cell markers through hierarchical regulation of Cas12a activity.
[0026] Fifthly, the present invention protects the application of the aforementioned TAC unit in the development of biosensors for constructing molecular diagnostic tools.
[0027] Sixthly, the present invention protects the application of the template-activator bifunctional unit in the preparation of molecular diagnostic reagents for detecting uracil DNA glycosylase (UDG).
[0028] Seventhly, the present invention protects the application of the method described above in any one of the following (A1)-(A3):
[0029] (A1) Application in the preparation of products for early cancer diagnosis;
[0030] (A2) Application in the development of biosensors;
[0031] (A3) Application in the preparation of molecular diagnostic reagents.
[0032] Eighthly, the present invention protects the application of any one of the aforementioned detection platforms in any one of the following (A1)-(A3): (A1) Application in the preparation of products for early cancer diagnosis;
[0033] (A2) Application in the development of biosensors;
[0034] (A3) Application in the preparation of molecular diagnostic reagents.
[0035] Beneficial effects
[0036] The method and application for hierarchical regulation of Cas12a activity driven by cross-lesion synthesis based on the template-activator bifunctional unit provided by the present invention have the following beneficial effects compared with the prior art:
[0037] ①Precise hierarchical regulation of Cas12a activity: The introduction of different DNA lesion types and the translesion synthesis characteristics of T7 RNA polymerase in the face of different lesion types synergistically act at the template level and the template-activator level to achieve fine hierarchical regulation of Cas12a activity, significantly improving the accuracy and flexibility of regulation;
[0038] ②Simple operation and economical cost: By constructing the TAC unit, the addition of exogenous activators and complex crRNA modification steps are avoided, effectively reducing the experimental components, making the operation more convenient and the experimental cost lower;
[0039] ③Reducing the risk of non-specific activation: Effectively reduces the problem of non-specific activation caused by the addition of exogenous activators in traditional methods;
[0040] ④High sensitivity and wide applicability of the detection platform: By constructing a "Light up" AIE fluorescence signal output platform, highly sensitive detection of cancer cell markers (such as UDG enzyme) is achieved, suitable for trace analysis and detection of complex biological samples. Brief Description of the Drawings
[0041] Figure 1 This is a schematic diagram of the principle of hierarchical regulation of Cas12a activity driven by translesion synthesis based on the TAC unit of the present invention.
[0042] Figure 2 Shows the direct influence of a series of transcriptional regulatory units on the hierarchical regulation of Cas12a activity at the activator level. Among them, Figure A is a schematic diagram of constructing the TAC unit, Figure B is a schematic diagram of the direct influence of a series of transcriptional regulatory units on the hierarchical regulation of Cas12a activity at the activator level, and Figure C is the direct influence of a series of transcriptional regulatory units on the hierarchical regulation of Cas12a activation rate at the activator level.
[0043] Figure 3 Shows the influence and secondary verification of transcriptional coupled activation of hierarchical regulation of Cas12a activity by a series of transcriptional regulatory units at two levels of template-activator. Among them, Figure A shows the influence of transcriptional coupled activation of hierarchical regulation of Cas12a activation rate by a series of transcriptional regulatory units at the template-activator level, Figure B shows the direct influence of different ratios of TAC-dU / -AP on the Cas12a activation rate at the activator level, and Figure C shows the influence of transcriptional coupled activation of different ratios of TAC-dU / -AP on the Cas12a activation rate at the template-activator level.
[0044] Figure 4 This is a schematic diagram of the "Light up" AIE fluorescence signal output platform.
[0045] Figure 5Performance analysis of the "Light up" AIE fluorescence signal output platform. Among them, Figures A - B are the sensitivity analysis diagrams of the "Light up" AIE fluorescence signal output platform for detecting different concentrations of UDG, and Figure C is the data diagram of the selectivity and anti-interference of the "Light up" AIE fluorescence signal output platform, and Figure D is the data diagram of the selectivity and anti-interference of the "Light up" AIE fluorescence signal output platform.
[0046] Figure 6 Practical application test of the constructed "Light up" AIE fluorescence signal output platform for detecting UDG in cell lysates of human cervical cancer cell line (Hela cells) and human lung adenocarcinoma cell line (A549 cells). Among them, Figures A - B are the sensitivity analysis diagrams of the "Light up" AIE fluorescence signal output platform for detecting UDG in different numbers of Hela cells in Hela cell lysate, and Figures C - D are the sensitivity analysis diagrams of the "Light up" AIE fluorescence signal output platform for detecting UDG in different numbers of A549 cells in A549 cell lysate. Detailed implementation mode
[0047] The present invention will be further described in detail below with reference to the embodiments. Reagents or instrument equipment not indicating the manufacturer are regarded as conventional products that can be purchased through the market.
[0048] Oligonucleotides (Sangon Biotech (Shanghai) Co., Ltd.); LbaCas12a, Buffer II buffer (Shanghai Jinan Biotechnology Co., Ltd.); UDG, T7 RNAP, rNTPs, UGI (NEB (Beijing) Co., Ltd.); Amplex Red (AR) (Shanghai Bide Pharmaceutical Technology Co., Ltd.).
[0049] Example 1 Synthesis of template-activator bifunctional unit TACs, the steps are as follows:
[0050] Mix the T7 promoter and the template (the ratio used is 1:1) in the hybridization buffer, react at 95 °C in a water bath for 10 min, and then slowly cool to room temperature to anneal and hybridize to form the TAC unit, which is stored at -20 °C for later use. Among them, the reaction buffer is hybridization Buffer (MgCl2: 100 mM; Tris: 200 mM; pH 8). The structural schematic diagram is as Figure 2 shown in Figure A.
[0051] Table 1. DNA sequences used in Example 1.
[0052]
[0053]
[0054] ‘ideoxyU’ refers to dU, and ‘idSp’ represents the AP site.
[0055] Example 2. An experiment to investigate the direct effect of TACs units on the activation rate of Cas12a at the activator level was carried out as follows:
[0056] As shown in the schematic diagram Figure 2 in Figure B, 0.5 nM TACs (TAC / TAC-dU / TAC-AP) was mixed with 10 nM crRNA, 10 nM Cas12a, 100 nM F-Q probe, Buffer II buffer and deionized water to make the total volume reach 100 μL. After incubation at 37 °C for 1 h, the fluorescence intensity was quantified. Using an F-7000 spectrophotometer with an excitation wavelength of 488 nm, the emission spectrum from 500 - 650 nm was recorded. The direct effect on the activation rate of Cas12a is shown in Figure 2 Figure C. As shown in Figure 2 , when the dU base is modified at different positions on the TAC unit, it does not affect the activity of Cas12a; while the AP site shows different activation effects (complete activation or partial activation). It is demonstrated that adjusting the type and position of the transcriptional regulatory unit modification at the activator level can have a direct effect on the activity of Cas12a.
[0057] The DNA sequence used in Example 2 is the same as that in Example 1, and the crRNA sequence used is:
[0058] 5’-UAAUUUCUACUAAGUGUAGAUGAGAGAGAGAGAGAGA GAGA-3’, as shown in SEQ ID NO: 16.
[0059] Example 3. An experiment to investigate the transcription-coupled activation effect of TACs units on the activation rate of Cas12a at the template-activator level was carried out as follows:
[0060] 0.5 nM TACs, 30 U T7 RNAP, 0.1 mM rNTPs, T7 RNAP reaction buffer and deionized water were mixed to make the volume reach 50 μL. The reaction was carried out at 37 °C for 1 h to complete the process of T7 RNAP transcribing different lengths of crRNA. Finally, 10 nM Cas12a, 100 nM reporter probe F-Q, Buffer II buffer and deionized water were added to make the total volume reach 100 μL. After incubation at 37 °C for 1 h, the fluorescence intensity was quantified, and the fluorescence measurement analysis was the same as in Example 2. The direct effect on the activation rate of Cas12a is shown in Figure 3 Figure A.
[0061] Based on the above conditions, the effects of TAC-dU and TAC-AP at different ratios on the Cas12a trans-cleavage activity at the activator level and the template-activator level were verified again, and the results are as Figure 3 B-C.
[0062] As Figure 3 shown, the presence of different transcription regulatory units (dU bases and AP sites) did cause differences in the length of RNA products. Among them, T7 RNAP can cross the dU base and successfully complete the transcription of the complete crRNA; however, T7 RNAP will be hindered by the AP site and generate crRNA fragments of different lengths. Using these products and their corresponding activators, fine-grained regulation of Cas12a activity (complete inhibition, complete activation or partial activation) was successfully achieved at the template-activator level.
[0063] The DNA sequences used in Example 3 are the same as those in Example 1.
[0064] Performance analysis of the "Light up" AIE fluorescence signal output platform constructed in Example 4 is as follows:
[0065] (1) Sensitivity analysis of the constructed "Light up" AIE fluorescence signal output platform is as follows:
[0066] Mix 2 nM TACs, different concentrations of UDG, UDG reaction buffer and deionized water to make the volume reach 20 μL, and react at 37 °C for 1 h to complete the process of UDG recognizing the dU base on TAC-dU2 and converting it into an AP site. Subsequently, add 30 U T7 RNAP, 0.1 mM rNTPs, T7 RNAP reaction buffer and deionized water and mix to make the volume reach 30 μL. React at 37 °C for 1 h to complete the process of T7 RNAP transcribing different lengths of crRNA. Finally, add 10 nM Cas12a, 100 nM 0.4 μM G4, Buffer II buffer and deionized water to make the total volume reach 50 μL. After reacting at 37 °C for 0.5 h, add 30 μM AR, 1 mM H2O2, 200 nM hemin, HEPES buffer and deionized water to make the volume reach 100 μL, and quantify the fluorescence intensity after reacting at room temperature for 10 min to achieve the quantitative detection of UDG. Use an F-7000 spectrophotometer with an excitation wavelength of 490 nm and record the emission spectrum at 550 - 750 nm.
[0067] Figure 5 A-B is the constructed "Light up" AIE fluorescence signal output platform at 0.00005 - 0.30 U·mL -1The fluorescence intensities corresponding to different UDG concentrations within the range were non-linearly fitted. From 0.00005 - 0.0040 U·mL -1 Within the range, the resorufin fluorescence intensity at 598 nm had a linear relationship with the UDG concentration, and the regression equation was F = 390.69c UDG + 74.539 (R 2 = 0.992), LOD = 0.0000108 U·mL -1 .
[0068] (2) Specificity and anti-interference analysis of the constructed "Light up" AIE fluorescence signal output platform are as follows:
[0069] Same as Example 4(1), except that the target proteases (FEN1, hOGG1, hAAG, T4 PNK, APE1, Nt.BbvCl, Exo.I) were changed.
[0070] As Figure 5 shown in C, the results indicate that the sensor has good specificity and anti-interference ability.
[0071] (3) UGI screening analysis of the constructed "Light up" AIE fluorescence signal output platform is as follows:
[0072] Same as Example 4(1), UGI can inhibit the activity of UDG by forming a highly stable and irreversible complex at a 1:1 stoichiometric ratio. The relative activity of UDG gradually decreases with the increase of UGI concentration and shows a dose-dependent relationship. The results are shown in 5D. The half-inhibitory concentration value of UGI inhibiting UDG activity is 0.0431 U·mL -1 .
[0073] Table 2. DNA sequences used in Example 4.
[0074]
[0075]
[0076] ‘ideoxyU’ refers to dU, and ‘idSp’ represents the AP site.
[0077] The steps for detecting UDG in cells using the "Light up" AIE fluorescence signal output platform constructed in Example 5 are as follows:
[0078] According to the product instruction manual, a nuclear protein extraction kit was used to isolate total proteases from different cell lines (HeLa, A549). Under the optimal experimental conditions, quantitative detection of intracellular UDG was achieved.
[0079] Same as Example 4(1), Figure 6 A - B is the non - linear fitting of the fluorescence intensity corresponding to different UDG concentrations in different Hela cells within the range of 5 - 1000 cells of the constructed "Light up" AIE fluorescence signal output platform. The resorufin fluorescence intensity at 598 nm shows a linear relationship with the UDG concentration within the range of 5 - 200 cells. The regression equation is F = 8.0107N - 3.7774 (R 2 = 0.994), LOD = 3 (cells).
[0080] Figure 6 C - D is the non - linear fitting of the fluorescence intensity corresponding to different UDG concentrations in different A549 cells within the range of 5 - 1000 cells of the constructed "Light up" AIE fluorescence signal output platform. The resorufin fluorescence intensity at 598 nm shows a linear relationship with the UDG concentration within the range of 25 - 500 cells. The regression equation is F = 2.5437N + 476.26 (R 2 = 0.993), LOD = 8 (cells).
[0081] The DNA sequences used in Example 5 are the same as those in Example 4.
[0082] The protection scope of the present invention is not limited to the above embodiments. Without departing from the spirit and scope of the inventive concept, changes and advantages that can be conceived by those skilled in the art are included in the present invention, and the scope of protection is defined by the appended claims.
Claims
1. A template-activator bifunctional unit, characterized in that, The bifunctional unit comprises: (i) T7 promoter and its complementary sequence; (ii) CRISPR array sequence; (iii) at least one DNA damage site selected from deoxyuridine base or apurinic / apyrimidinic site.
2. The template-activator bifunctional unit according to claim 1, wherein The CRISPR array sequence serves as both a crRNA transcription template and an activator of Cas12a, and the DNA damage site is located at a specific position on the template strand, including at least one of the 2nd, 12th, 20th, 27th, 33rd or 39th nucleotide positions.
3. A method for hierarchical regulation of Cas12a activity based on the template-activator bifunctional unit described in claim 1 or 2, characterized in that, Comprising the following steps: (1) Utilize the high-efficiency transcription property of T7 RNA polymerase to transcribe crRNA through the template-activator bifunctional unit described in claim 1; (2) Utilize the translesion synthesis property of T7 RNA polymerase to regulate the crRNA length and directly affect the trans-cleavage activity of Cas12a through the type and position of the DNA damage site, thereby achieving hierarchical regulation of the trans-cleavage activity of Cas12a.
4. The method according to claim 3, wherein: (a) When the TAC unit contains deoxyuridine base, at the template level, T7 RNA polymerase completes the transcription of full-length crRNA; at the activator level, the modification of deoxyuridine base at any position in the CRISPR array does not affect the trans-cleavage activity of Cas12a, thus fully activating the trans-cleavage activity of Cas12a; (b) When the TAC unit contains apurinic / apyrimidinic site, at the template level, the transcription of T7 RNA polymerase is blocked, generating truncated crRNA; at the activator level, apurinic / apyrimidinic sites at different positions will not affect, inhibit or partially inhibit the trans-cleavage activity of Cas12a, and through their synergistic effect, hierarchical and fine regulation of the trans-cleavage activity of Cas12a is achieved.
5. A detection platform based on the template-activator bifunctional unit according to claim 1 or 2 or the method according to claim 3 or 4, characterized in that, Combined with an aggregation-induced emission fluorescent probe for detecting base excision repair enzyme, specifically comprising the following steps: (1) Use uracil-DNA glycosylase to convert the deoxyuridine base in the template-activator bifunctional unit described in claim 1 into an apurinic / apyrimidinic site; (2) Transcribe crRNAs of different lengths through T7 RNA polymerase to regulate the activity of Cas12a; (3) Quantitatively analyze the concentration of uracil-DNA glycosylase through the change in aggregation-induced emission fluorescent signal.
6. The detection platform according to claim 5, characterized in that, Comprising the following specific steps: (1) Prepare a TAC-dU2 unit modified with dU base; (2) Use uracil-DNA glycosylase to specifically recognize and remove the dU base in the TAC-dU2 unit, converting it into an AP site; (3) After adding T7 RNA polymerase, the TAC-dU2 unit transcribes to generate full-length crRNA, or truncated crRNA fragments are generated due to the resulting TAC-AP2 unit; (4) Trigger the cleavage of the aggregation-induced emission probe by the trans-cleavage activity of Cas12a. The aggregation-induced emission fluorescent probe is a G-quadruplex / hemin system with peroxidase-like activity, which catalyzes the generation of reactive oxygen species from hydrogen peroxide and oxidizes Amplex Red to generate resorufin with typical AIE characteristics. element 7. The detection platform according to claim 5, characterized in that, The detection limit is 0.0000108 U·mL⁻¹, and the linear range is 0.00005 - 0.0040 U·mL⁻¹.
8. The template-activator bifunctional unit according to claim 1 or 2 is used in any one of the following (A1)-(A3): Use in the preparation of products for early cancer diagnosis; Use in the development of biosensors; Use in the preparation of molecular diagnostic reagents.
9. The method according to claim 3 or 4 is used in any one of the following (A1)-(A3): (A1) Use in the preparation of products for early cancer diagnosis; (A2) Use in the development of biosensors; (A3) Use in the preparation of molecular diagnostic reagents.
10. The detection platform according to any one of claims 5-7 is used in any one of the following (A1)-(A3): (A1) Use in the preparation of products for early cancer diagnosis; (A2) Use in the development of biosensors; (A3) Use in the preparation of molecular diagnostic reagents.
